An update on the pharmacogenetics of treating hypertension – Nature.com | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Self-Monitoring and Titration of Meds Drops BP in TASMIN SR – Medscape

Zydus gets USFDA nod for anti-hypertensive drug »

An update on the pharmacogenetics of treating hypertension – Nature.com

September 2, 2014 by 2012pharmaceutical

An update on the pharmacogenetics of treating hypertension Nature.com Interindividual genetic variability is one of the reasons for abnormal response to antihypertensive drugs.2 Over the past two decades, an increasing number of studies have been…

Source: news.google.com

See on Scoop.it – Cardiotoxicity

Posted in Uncategorized | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 1,254 other subscribers
Recent Posts
- 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
- Verily announced other organizational changes, 1/13/2023 January 16, 2023
- Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
- Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
- Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
- Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
- Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
- The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
- Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
- Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation October 4, 2022
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: